ABSTRACT
Objective
In the scope of the European Commission Initiative on Breast Cancer (ECIBC), the Monitoring and Evaluation (M&E) group was tasked to identify breast cancer screening programme (BCSP) performance indicators, including their acceptable and desirable levels, which are associated with breast cancer (BC) mortality. This paper documents the methodology used for the indicator selection.
Methods
The indicators were identified through a multi-stage process. First, a scoping review was conducted to identify existing performance indicators. Second, building on existing frameworks for making well-informed health care choices, a specific conceptual framework was developed to guide the indicator selection. Third, two group exercises including a rating and ranking survey were conducted for indicator selection using pre-determined criteria, such as: relevance, measurability, accurateness, ethics and understandability. The selected indicators were mapped onto a BC screening pathway developed by the M&E subgroup to illustrate the steps of BC screening common to all EU countries.
Results
A total of 96 indicators were identified from an initial list of 1,325 indicators. After removing redundant and irrelevant indicators and adding those missing, 39 candidate indicators underwent the rating and ranking exercise. Based on the results, the M&E subgroup selected 13 indicators: screening coverage, participation rate, recall rate, breast cancer detection rate, invasive breast cancer detection rate, cancers >20mm, cancers ≤10 mm, lymph node status, interval cancer rate, episode sensitivity, time interval between screening and first treatment, benign open surgical biopsy rate, and mastectomy rate
Conclusion
This systematic approach led to the identification of 13 BCSP candidate performance indicators to be further evaluated for their association with BC mortality.
MURATOV Sergei;
CANELO-AYBAR Carlos;
TARRIDE Jean-Eric;
COELLO Pablo Alonso;
DIMITROVA Nadya;
BORISCH Bettina;
CASTELLS Xavier;
DUFFY Stephen W;
FITZPATRICK Patricia;
FOLLMANN Markus;
GIORDANO Livia;
HOFVIND Solveig;
LEBEAU Annette;
QUINN Cecily;
TORRESIN Alberto;
VIALLI Claudia;
SIESLING Sabine;
PONTI Antonio;
ROSSI GIORGI Paolo;
SCHUNEMANN Holger;
NYSTROM Lennarth;
BROEDERS Mireille;
2020-09-01
BMC
JRC117491
1471-2407 (online),
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-020-07289-z,
https://publications.jrc.ec.europa.eu/repository/handle/JRC117491,
10.1186/s12885-020-07289-z (online),
